文献速递心外重症与机械循环支持

全磁悬浮左心室辅助装置外部流出道移植物阻塞的多中心评估

A multicenter evaluation of external outflow graft obstruction with a fully magnetically levitated left ventricular assist device.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-10-03

该多中心回顾性分析纳入2014年11月至2021年4月间8国17个心脏中心植入HeartMate 3左心室辅助装置的患者2108例,定义外部流出道移植物阻塞为影像学横截面积阻塞>25%,评估其患病率、病程及临床影响。62例(3.0%)确诊,中位支持时间953天,1至5年发病率逐年上升至9.1%;接受治疗干预者死亡9/53(17.0%)。作者认为该并发症虽不常见但需早期发现并保持警惕。

要点

  • 2108例HM 3 LVAD患者中62例(3.0%)发生外部流出道移植物阻塞。
  • 支持1、2、3、4、5年发病率分别为0.6%、2.8%、4.0%、5.2%、9.1%。
  • 接受治疗干预的53例中死亡9例(17.0%)。

核心结论

  • HM 3 LVAD支持患者可能发生外部流出道移植物阻塞,虽不常见,但支持1年后发病率逐渐增加。
  • 作者指出减少该并发症的工程学努力正在进行中,临床医生必须保持对早期发现的关注并保持警惕。

研究设计与样本

  • 多中心回顾性分析,纳入2014年11月至2021年4月间8个国家17个心脏中心植入的HM 3 LVAD患者2108例。
  • 外部流出道移植物阻塞定义为影像学(经皮血管造影、计算机断层扫描或血管内超声)横截面积阻塞>25%。
  • 计算患病率和年发病率,并分析外部流出道移植物阻塞患者的严重不良事件和结局(死亡、移植或装置更换)。

主要发现

  • 2108例患者中62例确诊外部流出道移植物阻塞,中位LVAD支持时间953天(四分位距600-1267天)。
  • 外部流出道移植物阻塞患病率为3.0%,支持1、2、3、4、5年发病率分别为0.6%、2.8%、4.0%、5.2%、9.1%。
  • 62例患者中9例观察,27例手术修正,15例经皮支架植入,8例心脏移植,2例干预前死亡;1例手术修正后接受支架植入。
  • 接受治疗干预的死亡率为9/53(17.0%)。

关键数值与推荐

  • 外部流出道移植物阻塞定义:影像学横截面积阻塞>25%。
  • 患病率3.0%;支持1、2、3、4、5年发病率分别为0.6%、2.8%、4.0%、5.2%、9.1%。
  • 治疗干预死亡率9/53(17.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The HeartMate 3 (HM 3; Abbott) left ventricular assist device (LVAD) has improved hemocompatibility-related adverse outcomes. In sporadic cases, external compression of the outflow graft causing obstruction (eOGO) can result from substance accumulation between the outflow graft and its bend relief. We sought to evaluate the prevalence, course, and clinical implications of eOGO in an international study. METHODS: A multicenter retrospective analysis of HM 3 LVADs implanted between November 2014 and April 2021 (n = 2108) was conducted across 17 cardiac centers in 8 countries. We defined eOGO as obstruction >25% in the cross-sectional area in imaging (percutaneous angiography, computed tomography, or intravascular ultrasound). The prevalence and annual incidence were calculated. Serious adverse events and outcomes (death, transplantation, or device exchange) were analyzed for eOGO cases. RESULTS: Of 2108 patients, 62 were diagnosed with eOGO at a median LVAD support duration of 953 (interquartile range, 600-1267) days. The prevalence of eOGO was 3.0% and the incidence at 1, 2, 3, 4, and 5 years of support was 0.6%, 2.8%, 4.0%, 5.2%, and 9.1%, respectively. Of 62 patients, 9 were observed, 27 underwent surgical revision, 15 underwent percutaneous stent implantation, 8 received a heart transplant, and 2 died before intervention. One patient underwent surgical revision and later stent implantation. The mortality with therapeutic intervention was 9/53 (17.0%). CONCLUSIONS: Although uncommon, HM 3 LVAD-supported patients might develop eOGO with an increasing incidence after 1 year of support. Although engineering efforts to reduce this complication are under way, clinicians must maintain a focus on early detection and remain vigilant.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Wert L, Stewart GC, Mehra MR, et al. A multicenter evaluation of external outflow graft obstruction with a fully magnetically levitated left ventricular assist device. J Thorac Cardiovasc Surg. 2022. PMID: 36562497. doi:10.1016/j.jtcvs.2022.09.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。